Table 2

BRCA1/2 testing rates for all patients and by period of diagnosis (period I and period II)

	All patients		Patients diagnosed in period I*		Patients diagnosed in period II*		P value
	n=250		n=171		n=79
	N	%	N	%	N	%
Tested: known germline pathogenic variant status	201	80.4	137	80.1	64	81.0	1.000
Untested: unknown germline pathogenic variant status	49	19.6	34	19.9	15	19.0
No test offered	45	18.0	33	19.3	12	15.2
Unsuccessful tumor test†	3	1.2	–	–	3	3.8
Rejected germline test‡	1	0.4	1	0.6	–	–
Test scenarios							<0.001
No test or inconclusive test result	48	19.2	33	19.3	15	19.0
Germline test only	97	38.8	93	54.4	4	5.1
Tumor test only§	61	24.4	20	11.7	41	51.9
Tumor+germline test	44	17.6	25¶	14.6	19	24.1

*Period I: January 1, 2016, until July 1, 2018. Period II: July 1, 2018, until January 1, 2020.
†Unsuccessful tumor test and no subsequent referral for germline test.
‡Patient withdrew from germline testing after tumor pathogenic variant was detected.
§All tumor tests were performed after July 1, 2018.
¶25 patients diagnosed in period I received both a tumor and germline test. The tumor tests were performed after a conclusive germline test indicated the absence of a germline pathogenic variant, to potentially detect a tumor pathogenic variant.